Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa

Table 2 Median haemoglobin improvement stratified by risk factors for anaemia (n = 814)

	Overall median change in Hb from baseline to 12 months ART	P-value*	P-value**
Overall	+1.6	-	<0.001
Gender
Male (n = 224)	+1.3	<0.001	<0.001
Female (n = 590)	+1.7		<0.001
ART regimen
AZT-free throughout (n = 646)	+1.5	0.480	<0.001
Any AZT exposure (n = 168)	+1.7		<0.001
Baseline anaemia severity
None (n = 240)	+0.4	<0.001	0.896
Mild (n = 228)	+1.5		<0.001
Moderate (n = 310)	+2.6		<0.001
Severe (n = 36)	+5.1		<0.001
CD4 cell count (cells/μL)
<100 (n = 383)	+1.7	0.052	<0.001
≥100 (n = 428)	+1.4		<0.001
Baseline HIV viral load (log copies/mL)
<5.00 (n = 498)	+1.4	<0.001	<0.001
5.00-5.49 (n = 211)	+1.8		<0.001
>5.50 (n = 100)	+2.1		<0.001
TB disease status
TB free (n = 566)	+1.5	0.198	<0.001
Referred TB (n = 131)	+1.6		<0.001
TB in first year of ART (n = 117)	+1.7		<0.001

*P-value for difference in overall median haemoglobin change from baseline to 12 months after starting ART.
**P-value for difference between median haemoglobin level at baseline and median haemoglobin level after 12 months of ART.
Abbreviations: ART, antiretroviral therapy; TB, tuberculosis.

ISSN: 1471-2334